
Aeglea BioTherapeutics Inc (AGLE)
NASDAQ
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Return on Assets (%) | -41.049 | -44.236 | -66.282 | -97.257 | -66.089 | -48.464 | -92.577 | -164.062 |
Return on Equity (%) | -106.47 | -48.076 | -75.316 | -122.743 | -80.928 | -58.81 | -124.868 | -289.167 |
Return on Invested Capital (%) | -107.649 | -48.971 | -77.395 | -127.536 | -82.895 | -59.792 | -130.079 | -163.595 |
Operating Margin (%) | -468.842 | -523.266 | -1140.638 | N/A | N/A | -350.392 | -3604.594 | -38241.084 |
Net Profit Margin (%) | -468.842 | -523.266 | -1140.638 | N/A | N/A | -351.145 | -3598.755 | -38238.149 |
Book Value Per Share | 2.81 | 1.963 | 2.036 | 1.579 | 2.456 | 1.439 | 0.714 | 20.624 |
Earnings Per Share | -0.968 | -1.062 | -1.339 | -2.056 | -1.421 | -1.128 | -1.189 | -26.017 |
Cash Per Share | 2.131 | 0.5 | 0.678 | 0.506 | 1.583 | 0.26 | 0.495 | 14.506 |
Working Capital Per Share | 2.788 | 1.925 | 2.006 | 1.475 | 2.342 | 1.35 | 0.675 | 23.771 |
Operating Profit Per Share | 0.207 | 0.203 | 0.117 | N/A | N/A | 0.321 | 0.033 | 0.068 |
EBIT Per Share | -0.968 | -1.062 | -1.339 | -2.056 | -1.421 | -1.126 | -1.191 | -26.019 |
EBITDA Per Share | -0.968 | -1.062 | -1.339 | -2.056 | -1.421 | -1.126 | -1.191 | -26.019 |
Free Cash Flow Per Share | -0.965 | -1.048 | -1.335 | -2.028 | -1.363 | -1.145 | -1.208 | -26.074 |
Fin d'année 31 Décembre 2023 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Actions en circulation | 13,43M | 16,67M | 24,14M | 29,08M | 47,96M | 49,36M | N/A | N/A |
Fin d'année 31 Décembre 2023 | Déc 2022 | Mar 2023 | Juin 2023 | Sept 2023 | Déc 2023 | Mar 2024 | Juin 2024 | Sept 2024 |
---|---|---|---|---|---|---|---|---|
USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
Actions en circulation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Assets (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Equity (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Return on Invested Capital (%) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Margin (%) | N/A | -9322.222 | N/A | N/A | N/A | N/A | N/A | N/A |
Net Profit Margin (%) | N/A | -9304.04 | N/A | N/A | N/A | N/A | N/A | N/A |
Sales Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Earnings Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Cash Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Working Capital Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Operating Profit Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBIT Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
EBITDA Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Free Cash Flow Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Inventory Turnover (Days) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Capitalisation boursière | 48,63M |
Ratio cours/bénéfice | -0,22 |
Ratio prix/ventes | 84,87 |
Ratio prix/liquidités | 0,4 |
Ratio prix/valeur comptable | 0,28 |
Rendement de dividende | - |
Actions en circulation | 4,05M |
Volume moyen (1 semaine) | 0 |
Volume moyen (1 mois) | 0 |
Variation sur 52 semaines | - |
Plus haut sur 52 semaines | - |
Plus bas sur 52 semaines | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales